This is the on the internet version of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers can indicator up listed here to get it shipped each individual Thursday to their inbox.
Very good morning! The 1st quarter was the fourth-finest quarter for biotech funding on report, in accordance to Jefferies. But stubbornly large inflation doesn’t bode perfectly for the fascination rate cuts that the biotech industry was trying to get. Glimpse out, stocks! Mail me feelings, reviews, and questions to [email protected].
The inside story of Enhertu’s pan-tumor approval
Cancer drug background was produced previous Friday. Enhertu, the blockbuster antibody-drug conjugate found out by Daiichi Sankyo and co-designed by AstraZeneca, was accredited in the U.S. to deal with any affected individual with sophisticated, HER2-good most cancers, irrespective of exactly where the tumor is located in the physique.
Continue to STAT+ to examine the entire story…